(Total Views: 584)
Posted On: 05/31/2022 10:45:06 PM
Post# of 153904
Quote:
The question that requires asking & answering is why is it that this phenomenon is observed when Leronlimab is introduced & bound to the CCR5 receptors, but when HIV or CCL5 RANTES is bound in mass quantity,
In the HIV combo therapy trial they didn't break down CCR5+CD4+ T cells counts just CD4+ T cell counts. With CD4 + T cells there was a 48% increase from baseline to 25 weeks after first injection.
(2)
(0)
